Cargando…
Metastatic squamous cell non-small-cell lung cancer (NSCLC): disrupting the drug treatment paradigm with immunotherapies
Lung cancer is the third most commonly diagnosed cancer and the leading cause of cancer-related death in the United States. Unlike non-squamous NSCLC, squamous NSCLC rarely harbor epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) mutations for which there are directed ther...
Autor principal: | Scarpace, Sarah L |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Just Medical Media Limited
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4630973/ https://www.ncbi.nlm.nih.gov/pubmed/26576187 http://dx.doi.org/10.7573/dic.212289 |
Ejemplares similares
-
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)
por: Brahmer, Julie R., et al.
Publicado: (2018) -
Immunotherapy in Non-Small Cell Lung Cancer: Shifting Prognostic Paradigms
por: Barnet, Megan B., et al.
Publicado: (2018) -
Treatment Paradigms for Patients with Metastatic Non-Small Cell Lung Cancer, Squamous Lung Cancer: First, Second, and Third-Line
por: Al-Farsi, Abdulaziz, et al.
Publicado: (2014) -
Immunotherapy and Vaccination in Surgically Resectable Non-Small Cell Lung Cancer (NSCLC)
por: Chiu, Li-Chung, et al.
Publicado: (2021) -
Changing paradigm in advanced and metastatic non-small cell lung cancer
por: Uprety, Dipesh, et al.
Publicado: (2020)